Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

NCT06225622 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Irinotecan Liposome
DRUG: Oxaliplatin
DRUG: 5-FU
DRUG: LV
DRUG: Bevacizumab
DRUG: Cetuximab

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]